📊 KPHMW Key Takeaways
Is Kiora Pharmaceuticals Inc. (KPHMW) a Good Investment?
Kiora Pharmaceuticals is a pre-revenue development-stage biotech with zero commercial revenue and annual operating losses exceeding $12M, supported only by $8.7M in cash—providing approximately 10 months of runway at current burn rates. Without imminent product approval or commercial inflection, the company faces severe dilution risk and high probability of capital restructuring or insolvency within 12 months.
Kiora is pre-revenue with sharply deteriorating profitability (net loss -$10.8M, -401% YoY) and persistent negative free cash flow, reflecting an early-stage, cash-burning profile. Liquidity is strong (current ratio ~6x) and leverage is minimal, but the $8.7M cash balance covers less than a year of recent burn. On fundamentals alone, expected financing needs and dilution risk outweigh near-term operational upside.
Why Buy Kiora Pharmaceuticals Inc. Stock? KPHMW Key Strengths
- Exceptional liquidity position with 5.99x current and quick ratios far exceeding industry norms
- Minimal debt burden with only $278K in long-term debt and 0.02x debt-to-equity ratio
- Reasonable stockholders' equity base of $16.1M providing modest financial cushion
- Strong liquidity (current/quick ratio 5.99x)
- Very low leverage (Debt/Equity 0.02x)
- Low capex needs supporting operating flexibility
KPHMW Stock Risks: Kiora Pharmaceuticals Inc. Investment Risks
- Zero commercial revenue with no approved products generating sales, indicating pre-commercialization stage with undefined timeline to profitability
- Unsustainable cash burn of $10.1M annually against $8.7M cash position, providing only ~10 months operational runway before external funding necessity
- Severe dilution risk from imminent capital raise combined with negative unit economics and no clear path to profitability
- No revenue (-100% YoY) with unclear commercialization timing
- High cash burn (OCF -$9.96M; FCF -$10.07M) implying short runway
- Potential dilution/going-concern risk absent new funding
Key Metrics to Watch
- Cash runway depletion rate and timing of next financing round
- Clinical trial progress and FDA approval milestones for pipeline assets
- Burn rate trajectory and operating expense management
- Operating cash flow (burn rate)
- Cash & equivalents (runway months)
Kiora Pharmaceuticals Inc. (KPHMW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.99x current ratio provides a solid financial cushion.
KPHMW Profit Margin, ROE & Profitability Analysis
KPHMW vs Healthcare Sector: How Kiora Pharmaceuticals Inc. Compares
How Kiora Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kiora Pharmaceuticals Inc. Stock Overvalued? KPHMW Valuation Analysis 2026
Based on fundamental analysis, Kiora Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kiora Pharmaceuticals Inc. Balance Sheet: KPHMW Debt, Cash & Liquidity
KPHMW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kiora Pharmaceuticals Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $0.87 reflects profitable operations.
KPHMW Revenue Growth, EPS Growth & YoY Performance
KPHMW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $26.8K | $0.01 |
| Q2 2025 | N/A | -$2.2M | $-0.53 |
| Q1 2025 | N/A | -$2.2M | $-0.52 |
| Q3 2024 | N/A | -$3.4M | $-0.81 |
| Q2 2024 | N/A | -$2.2M | $-0.53 |
| Q1 2024 | N/A | -$1.9M | $0.38 |
| Q3 2020 | N/A | -$2.0M | N/A |
| Q2 2020 | N/A | -$966.5K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kiora Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
KPHMW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kiora Pharmaceuticals Inc. (CIK: 0001372514)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KPHMW
What is the AI rating for KPHMW?
Kiora Pharmaceuticals Inc. (KPHMW) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KPHMW's key strengths?
Claude: Exceptional liquidity position with 5.99x current and quick ratios far exceeding industry norms. Minimal debt burden with only $278K in long-term debt and 0.02x debt-to-equity ratio. ChatGPT: Strong liquidity (current/quick ratio 5.99x). Very low leverage (Debt/Equity 0.02x).
What are the risks of investing in KPHMW?
Claude: Zero commercial revenue with no approved products generating sales, indicating pre-commercialization stage with undefined timeline to profitability. Unsustainable cash burn of $10.1M annually against $8.7M cash position, providing only ~10 months operational runway before external funding necessity. ChatGPT: No revenue (-100% YoY) with unclear commercialization timing. High cash burn (OCF -$9.96M; FCF -$10.07M) implying short runway.
What is KPHMW's revenue and growth?
Kiora Pharmaceuticals Inc. reported revenue of $0.0.
Does KPHMW pay dividends?
Kiora Pharmaceuticals Inc. does not currently pay dividends.
Where can I find KPHMW SEC filings?
Official SEC filings for Kiora Pharmaceuticals Inc. (CIK: 0001372514) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KPHMW's EPS?
Kiora Pharmaceuticals Inc. has a diluted EPS of $-2.64.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KPHMW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kiora Pharmaceuticals Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KPHMW stock overvalued or undervalued?
Valuation metrics for KPHMW: ROE of -67.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KPHMW stock in 2026?
Our dual AI analysis gives Kiora Pharmaceuticals Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KPHMW's free cash flow?
Kiora Pharmaceuticals Inc.'s operating cash flow is $-10.0M, with capital expenditures of $110.8K.
How does KPHMW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -67.2% (avg: 15%), current ratio 5.99 (avg: 2).